TocilizumabV1, Main, Exploration, bibRecord, 000632

[Efficacy and safety of tocilizumab in patients with Takayasu arteritis].

Identifieur interne : 000632 ( Main/Exploration ); précédent : 000631; suivant : 000633

[Efficacy and safety of tocilizumab in patients with Takayasu arteritis].

Auteurs : H. Liao [République populaire de Chine] ; L L Pan ; J. Du ; N. Gao ; T. Wang

Source :

Zhonghua nei ke za zhi [ 0578-1426 ] ; 2019.

RBID : pubmed:31159524

Descripteurs français

KwdFr :
- Anticorps monoclonaux humanisés (administration et posologie), Anticorps monoclonaux humanisés (usage thérapeutique), Cyclophosphamide (administration et posologie), Cyclophosphamide (usage thérapeutique), Humains, Maladie de Takayashu (anatomopathologie), Maladie de Takayashu (traitement médicamenteux), Résultat thérapeutique, Études rétrospectives.
MESH :
- administration et posologie : Anticorps monoclonaux humanisés, Cyclophosphamide.
- anatomopathologie : Maladie de Takayashu.
- traitement médicamenteux : Maladie de Takayashu.
- usage thérapeutique : Anticorps monoclonaux humanisés, Cyclophosphamide.
- Humains, Résultat thérapeutique, Études rétrospectives.

English descriptors

KwdEn :
- Antibodies, Monoclonal, Humanized (administration & dosage), Antibodies, Monoclonal, Humanized (therapeutic use), Cyclophosphamide (administration & dosage), Cyclophosphamide (therapeutic use), Humans, Retrospective Studies, Takayasu Arteritis (drug therapy), Takayasu Arteritis (pathology), Treatment Outcome.
MESH :
- chemical , administration & dosage : Antibodies, Monoclonal, Humanized, Cyclophosphamide.
- chemical , therapeutic use : Antibodies, Monoclonal, Humanized, Cyclophosphamide.
- drug therapy : Takayasu Arteritis.
- pathology : Takayasu Arteritis.
- Humans, Retrospective Studies, Treatment Outcome.

Abstract

Objective: To assess the efficacy and safety of tocilizumab and cyclophosphamide in patients with Takayasu arteritis (TA). Methods: Twenty-seven TA patients treated with tocilizumab (TCZ group) and 22 treated with cyclophosphamide (CTX group) were enrolled and retrospectively analyzed. The duration of treatment was 6 months. Disease activity and side effects were compared between the two groups. Results: After treatment, the median C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and disease activity scores in TCZ group were significantly lower than those in CTX group respectively [ESR 3 mm/1h vs. 8 mm/1h; CRP 0.13 mg/L vs. 1.09 mg/L; National Institutes of Health (NIH) score 0(0,1) vs. 0(1,1); the Indian Takayasu clinical activity score (ITAS 2010) 0(0,2) vs. 2(0,3.5), and the Indian Takayasu activity score with the acute phase response (ITAS-A) 0(0,2) vs. 2.5(0,3.5); all P<0.05]. The daily prednisone doses before treatment and after treatment in TCZ group were significantly lower than those in CTX group [(20.1±15.9) mg/d vs. (39.3±16.7) mg/d;(5.1±4.2)mg/d vs. (12.1±4.6) mg/d,both P<0.05)].The incidence of drug-related side effects in TCZ group was significantly lower than that in CTX group, which was 22.2% vs. 54.5% (P<0.05). Conclusion: Compared with CTX treatment, TCZ treatment for TA with less prednisone has better efficacy and safety.

DOI: 10.3760/cma.j.issn.0578-1426.2019.06.009
PubMed: 31159524

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Efficacy and safety of tocilizumab in patients with Takayasu arteritis].</title>
<author><name sortKey="Liao, H" sort="Liao, H" uniqKey="Liao H" first="H" last="Liao">H. Liao</name>
<affiliation wicri:level="1"><nlm:affiliation>Departments of Rheumatology and Immunology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Departments of Rheumatology and Immunology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pan, L L" sort="Pan, L L" uniqKey="Pan L" first="L L" last="Pan">L L Pan</name>
</author>
<author><name sortKey="Du, J" sort="Du, J" uniqKey="Du J" first="J" last="Du">J. Du</name>
</author>
<author><name sortKey="Gao, N" sort="Gao, N" uniqKey="Gao N" first="N" last="Gao">N. Gao</name>
</author>
<author><name sortKey="Wang, T" sort="Wang, T" uniqKey="Wang T" first="T" last="Wang">T. Wang</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2019">2019</date>
<idno type="RBID">pubmed:31159524</idno>
<idno type="pmid">31159524</idno>
<idno type="doi">10.3760/cma.j.issn.0578-1426.2019.06.009</idno>
<idno type="wicri:Area/PubMed/Corpus">000375</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000375</idno>
<idno type="wicri:Area/PubMed/Curation">000375</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000375</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000246</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000246</idno>
<idno type="wicri:Area/Ncbi/Merge">001F99</idno>
<idno type="wicri:Area/Ncbi/Curation">001F99</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001F99</idno>
<idno type="wicri:doubleKey">0578-1426:2019:Liao H:efficacy:and:safety</idno>
<idno type="wicri:Area/Main/Merge">000632</idno>
<idno type="wicri:Area/Main/Curation">000632</idno>
<idno type="wicri:Area/Main/Exploration">000632</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Efficacy and safety of tocilizumab in patients with Takayasu arteritis].</title>
<author><name sortKey="Liao, H" sort="Liao, H" uniqKey="Liao H" first="H" last="Liao">H. Liao</name>
<affiliation wicri:level="1"><nlm:affiliation>Departments of Rheumatology and Immunology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Departments of Rheumatology and Immunology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pan, L L" sort="Pan, L L" uniqKey="Pan L" first="L L" last="Pan">L L Pan</name>
</author>
<author><name sortKey="Du, J" sort="Du, J" uniqKey="Du J" first="J" last="Du">J. Du</name>
</author>
<author><name sortKey="Gao, N" sort="Gao, N" uniqKey="Gao N" first="N" last="Gao">N. Gao</name>
</author>
<author><name sortKey="Wang, T" sort="Wang, T" uniqKey="Wang T" first="T" last="Wang">T. Wang</name>
</author>
</analytic>
<series><title level="j">Zhonghua nei ke za zhi</title>
<idno type="ISSN">0578-1426</idno>
<imprint><date when="2019" type="published">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal, Humanized (administration & dosage)</term>
<term>Antibodies, Monoclonal, Humanized (therapeutic use)</term>
<term>Cyclophosphamide (administration & dosage)</term>
<term>Cyclophosphamide (therapeutic use)</term>
<term>Humans</term>
<term>Retrospective Studies</term>
<term>Takayasu Arteritis (drug therapy)</term>
<term>Takayasu Arteritis (pathology)</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps monoclonaux humanisés (administration et posologie)</term>
<term>Anticorps monoclonaux humanisés (usage thérapeutique)</term>
<term>Cyclophosphamide (administration et posologie)</term>
<term>Cyclophosphamide (usage thérapeutique)</term>
<term>Humains</term>
<term>Maladie de Takayashu (anatomopathologie)</term>
<term>Maladie de Takayashu (traitement médicamenteux)</term>
<term>Résultat thérapeutique</term>
<term>Études rétrospectives</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term>
<term>Cyclophosphamide</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term>
<term>Cyclophosphamide</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term>
<term>Cyclophosphamide</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Maladie de Takayashu</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Takayasu Arteritis</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Takayasu Arteritis</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Maladie de Takayashu</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term>
<term>Cyclophosphamide</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Retrospective Studies</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Humains</term>
<term>Résultat thérapeutique</term>
<term>Études rétrospectives</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><b>Objective:</b>
 To assess the efficacy and safety of tocilizumab and cyclophosphamide in patients with Takayasu arteritis (TA). <b>Methods:</b>
 Twenty-seven TA patients treated with tocilizumab (TCZ group) and 22 treated with cyclophosphamide (CTX group) were enrolled and retrospectively analyzed. The duration of treatment was 6 months. Disease activity and side effects were compared between the two groups. <b>Results:</b>
 After treatment, the median C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and disease activity scores in TCZ group were significantly lower than those in CTX group respectively [ESR 3 mm/1h vs. 8 mm/1h; CRP 0.13 mg/L vs. 1.09 mg/L; National Institutes of Health (NIH) score 0(0,1) vs. 0(1,1); the Indian Takayasu clinical activity score (ITAS 2010) 0(0,2) vs. 2(0,3.5), and the Indian Takayasu activity score with the acute phase response (ITAS-A) 0(0,2) vs. 2.5(0,3.5); all <i>P<</i>
0.05]. The daily prednisone doses before treatment and after treatment in TCZ group were significantly lower than those in CTX group [(20.1±15.9) mg/d vs. (39.3±16.7) mg/d;(5.1±4.2)mg/d vs. (12.1±4.6) mg/d,both <i>P<</i>
0.05)].The incidence of drug-related side effects in TCZ group was significantly lower than that in CTX group, which was 22.2% vs. 54.5% (<i>P<</i>
0.05). <b>Conclusion:</b>
 Compared with CTX treatment, TCZ treatment for TA with less prednisone has better efficacy and safety.</div>
</front>
</TEI>
<affiliations><list><country><li>République populaire de Chine</li>
</country>
<settlement><li>Pékin</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Du, J" sort="Du, J" uniqKey="Du J" first="J" last="Du">J. Du</name>
<name sortKey="Gao, N" sort="Gao, N" uniqKey="Gao N" first="N" last="Gao">N. Gao</name>
<name sortKey="Pan, L L" sort="Pan, L L" uniqKey="Pan L" first="L L" last="Pan">L L Pan</name>
<name sortKey="Wang, T" sort="Wang, T" uniqKey="Wang T" first="T" last="Wang">T. Wang</name>
</noCountry>
<country name="République populaire de Chine"><noRegion><name sortKey="Liao, H" sort="Liao, H" uniqKey="Liao H" first="H" last="Liao">H. Liao</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000632 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000632 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:31159524
   |texte=   [Efficacy and safety of tocilizumab in patients with Takayasu arteritis].
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:31159524" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a TocilizumabV1

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021

Serveur d'exploration Tocilizumab

[Efficacy and safety of tocilizumab in patients with Takayasu arteritis].

[Efficacy and safety of tocilizumab in patients with Takayasu arteritis].

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration Tocilizumab
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.